Official Title
Prevention of Acute Pancreatitis After Endoscopic Interventions
Phase
Phase 1Lead Sponsor
Vitebsk State Medical UniversityStudy Type
InterventionalStatus
Unknown statusIndication/Condition
Cholangiolitis Acute PancreatitisIntervention/Treatment
MeksibelStudy Participants
90The aim of the study is to develop a method for the prevention of acute pancreatitis after minimally invasive interventions of the bile ducts using a drug regimen.
A prospective, randomized, single-center study is planned to identify the most effective drug regimen in order to prevent the development of acute pancreatitis after transpapillary interventions of the bile ducts.
Intravenous 0.1 30 minutes before the procedure and 0.1 once a day for 3 days after the procedure
Into the rectum 1 hour before the procedure and 1 candle 1 time a day for 3 days after the procedure
Intravenous 15 mg 30 minutes before the procedure and 15 mg once a day for 3 days after the procedure
Intravenous 3 ml 30 minutes before the procedure and 3 ml once a day for 3 days after the procedure
Inclusion Criteria: Patients with cholangiolithiasis. Patients with benign formations of the bile ducts. Patients with malignant formations of the bile ducts. Patients with extrahepatic bile duct cysts. Patients with biliary hypertension of unknown etiology. Patients with cholangitis. Patients with extrahepatic bile duct strictures. Patients suffering from oncopathology of the head of the pancreas, complicated by obstructive jaundice. Patients with malignant pathology of the pancreas. Patients with benign pancreatic pathology. Exclusion Criteria: ASA scale> III (severe concomitant cardiovascular pathology) Severe pathology of the respiratory system. Acute period of myocardial infarction. Acute period of cerebral infarction.